^
    1d
    CD45BE-HSPC + CART-45 Cells (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, University of Pennsylvania
    New P1 trial
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    2d
    EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Daihong Liu
    New P1/2 trial
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    4d
    Mapping malignant T-cell states and immune circuits in Sézary syndrome by single-cell analysis. (PubMed, J Eur Acad Dermatol Venereol)
    This is one of the most comprehensive single-cell studies of leukaemic CTCL to date. We uncover new malignant T-cell states, broaden the known repertoire of KIR expression, and propose mechanisms of immune evasion that may contribute to treatment resistance. These findings lay the groundwork for subtype-specific and microenvironment-informed therapeutic strategies in Sézary syndrome, with potential implications for guiding targeted therapy selection but require validation in larger, independent cohorts.
    Journal
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • IL10 (Interleukin 10) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3) • NR4A1 (Nuclear Receptor Subfamily 4 Group A Member 1) • ITGB1 (Integrin Subunit Beta 1)
    5d
    APHP240605: CITY (2024-520294-13-00)
    P1, N=35, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P1 trial
    6d
    Beyond CD30: Dual-Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides. (PubMed, Adv Sci (Weinh))
    Anti-apoptotic BCL2 was upregulated in all tumor cells from nonresponsive lesions, especially in CD30- subsets. We further confirmed a potent synergy between BV and BCL2 inhibitors in tumor cell lines, indicating a promising strategy to overcome resistance in CTCL.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IFNG (Interferon, gamma) • IFNA1 (Interferon Alpha 1)
    |
    Adcetris (brentuximab vedotin)
    9d
    From Cell Lines to Avatars: Charting the Future of Preclinical Modeling in T-Cell Malignancies. (PubMed, Cells)
    These "avatar" models preserve vital tumor heterogeneity and microenvironmental context, offering superior predictive value. The systematic development and integration of these next-generation models are essential to bridge the translational gap and advance precision medicine for all patients with T-cell malignancies.
    Preclinical • Review • Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • NOTCH1 (Notch 1)
    |
    NPM1 mutation • ALK fusion
    9d
    A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=8, Terminated, Otsuka Pharmaceutical Co., Ltd. | N=61 --> 8
    Enrollment change
    |
    tolinapant (ASTX660)
    10d
    PRESERVE I: A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Ossium Health, Inc. | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    15d
    BK polyomavirus-associated progressive multifocal leukoencephalopathy following mogamulizumab therapy for erythrodermic mycosis fungoides. (PubMed, Front Cell Infect Microbiol)
    This is the first documented case of BKPyV-associated PML in a Mogamulizumab-treated patient. These findings highlight intra-host heterogeneity at the protein level, possibly reflecting compartment-specific viral evolution, and underscore the need for vigilant BKPyV and JCPyV monitoring during Mogamulizumab treatment.
    Journal
    |
    CCR4 (C-C Motif Chemokine Receptor 4)
    |
    Poteligeo (mogamulizumab-kpkc)
    16d
    Mycosis fungoides and Sézary syndrome. (PubMed, Br J Haematol)
    Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common cutaneous T-cell lymphomas, arising from mature CD4+ memory T cells. Diagnosis is complex and relies on clinicopathological correlation, immunophenotyping and molecular clonality testing, while management is stage-adapted, with potentially curative outcomes achievable only in selected patients through allogeneic haematopoietic stem cell transplantation.
    Review • Journal
    |
    CD4 (CD4 Molecule)
    17d
    APHP240605: CITY (2024-520294-13-00)
    P1, N=27, Not yet recruiting, Assistance Publique Hopitaux De Paris
    New P1 trial
    17d
    PTX-100-02-2024: A Phase 2 Study of PTX-100 Monotherapy in Patients with r/r CTCL (2025-521852-45-00)
    P1/2, N=25, Recruiting, Prescient Therapeutics Limited
    New P1/2 trial
    |
    PTX-100